ホームポートフォリオウォッチリストコミュニティ発見スクリーナー
NOT FOR DISTRIBUTION
Loading...
  • 株式
  • /
  • ヘルスケア
6時間前に更新
VEEV logo

Veeva Systems Inc.NYSE:VEEV 株式レポート

時価総額 US$42.9b
6時間前に更新
株価
n/a
1Y-5.5%
7D1.1%
1D-0.4%
ポートフォリオ価値
​
表示

Veeva Systems Inc.

NYSE:VEEV 株式レポート

時価総額:US$42.9b

  • 会社概要
    • 評価
    • 将来の成長
    • 過去の実績
    • 財務の健全性
    • 配当金
  • マネジメント
  • 所有権
  • その他の情報
  • 株式コミュニティ

Veeva Systems(VEEV)株式概要

Veeva Systems Inc.は、北米、欧州、アジア太平洋地域、中東、アフリカ、中南米のライフサイエンス業界向けにクラウドベースのソフトウェアを提供している。 詳細

VEEV ファンダメンタル分析
スノーフレーク・スコア
評価2/6
将来の成長1/6
過去の実績5/6
財務の健全性6/6
配当金0/6

報酬

当社が推定した公正価値より15.3%で取引されている

収益は年間12.65%増加すると予測されています

過去1年間で収益は25.3%増加しました

リスク分析

VEEV リスクチェックを通過した。

VEEV Community Fair Values

Create Narrative

See what 275 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

AN
AnalystConsensusTarget
4.9% 割高 内在価値ディスカウント
AnalystConsensusTarget
•28d ago

Pharma Wins And New Partnerships Will Drive Cloud Momentum In Coming Quarters

1.2k
0
123
AN
AnalystHighTarget
24.6% 割安 内在価値ディスカウント
AnalystHighTarget
•3h ago

Rising Life Sciences Cloud Standardization And AI Adoption Will Support Strong Long Term Upside

84
0
3
AN
AnalystLowTarget
15.9% 割高 内在価値ディスカウント
AnalystLowTarget
•14d ago

AI And Data Expansion Will Define Future Potential While Current Risks Keep Expectations Tame

113
0
5

Top Community Narratives

VEEV logo
Veeva Systems
31.2% 割安 内在価値ディスカウント

AI-Powered Veeva Systems Poised for Solid Growth Amid Regulatory Stability

View narrative
JO
John_Eric
Emerging Author
John_Eric
Updated 27 Aug
Read Narrative

Top Community Narratives

VEEV logo
Veeva Systems
31.2% 割安 内在価値ディスカウント

AI-Powered Veeva Systems Poised for Solid Growth Amid Regulatory Stability

View narrative
JO
John_Eric
Emerging Author
John_Eric
Updated 27 Aug
Read Narrative

Top Analyst Narratives

AN
AnalystConsensusTarget
4.9% 割高 内在価値ディスカウント
AnalystConsensusTarget
•28d ago

Pharma Wins And New Partnerships Will Drive Cloud Momentum In Coming Quarters

1.2k
0
123
AN
AnalystHighTarget
24.6% 割安 内在価値ディスカウント
AnalystHighTarget
•3h ago

Rising Life Sciences Cloud Standardization And AI Adoption Will Support Strong Long Term Upside

84
0
3
AN
AnalystLowTarget
15.9% 割高 内在価値ディスカウント
AnalystLowTarget
•14d ago

AI And Data Expansion Will Define Future Potential While Current Risks Keep Expectations Tame

113
0
5
View all narratives

Veeva Systems Inc. 競合他社

Doximity

Symbol: NYSE:DOCS
Market cap: US$4.6b

Waystar Holding

Symbol: NasdaqGS:WAY
Market cap: US$5.1b

GoodRx Holdings

Symbol: NasdaqGS:GDRX
Market cap: US$1.2b

HealthStream

Symbol: NasdaqGS:HSTM
Market cap: US$900.1m

価格と性能

株価の高値、安値、推移の概要Veeva Systems
過去の株価
現在の株価US$263.75
52週高値US$310.50
52週安値US$148.05
ベータ0.97
1ヶ月の変化8.65%
3ヶ月変化72.05%
1年変化-5.49%
3年間の変化29.80%
5年間の変化-11.70%
IPOからの変化609.77%

最新ニュース

User avatar
ナラティブ更新 • Sep 03

VEEV: Elevated AI Optimism Will Pressure CRM Expectations Going Forward

Analysts have lifted their fair value estimate for Veeva Systems from $165.00 to about $227.65, reflecting higher assumed revenue growth and a richer future P/E multiple, partly supported by recent price target increases tied to expected billings strength, CRM wins, and perceived insulation from AI disruption. Analyst Commentary Recent Street research on Veeva Systems highlights a generally constructive view, with several firms lifting price targets and pointing to strengths in CRM, subscription growth and the company’s positioning around AI.
Seeking Alpha • Aug 27

Veeva Systems: A Combination Of Growth, Margins, And Financial Strength

Summary Veeva Systems is rated a buy, supported by durable double-digit revenue growth, expanding profitability, and a robust, debt-light balance sheet. VEEV's recurring subscription model drives high margins—Q1 FY2027 saw 75% GAAP gross margin and 86.4% subscription gross margin, with continued product adoption fueling growth. Management raised FY2027 guidance and targets a $6 billion revenue run rate by 2030, with Q2 revenue expected to exceed guidance. Valuation risk has moderated, with VEEV now trading at 44x trailing and 38x forward earnings as the company grows into its premium multiple. Read the full article on Seeking Alpha

Recent updates

User avatar
ナラティブ更新 • Sep 03

VEEV: Elevated AI Optimism Will Pressure CRM Expectations Going Forward

Analysts have lifted their fair value estimate for Veeva Systems from $165.00 to about $227.65, reflecting higher assumed revenue growth and a richer future P/E multiple, partly supported by recent price target increases tied to expected billings strength, CRM wins, and perceived insulation from AI disruption. Analyst Commentary Recent Street research on Veeva Systems highlights a generally constructive view, with several firms lifting price targets and pointing to strengths in CRM, subscription growth and the company’s positioning around AI.
Seeking Alpha • Aug 27

Veeva Systems: A Combination Of Growth, Margins, And Financial Strength

Summary Veeva Systems is rated a buy, supported by durable double-digit revenue growth, expanding profitability, and a robust, debt-light balance sheet. VEEV's recurring subscription model drives high margins—Q1 FY2027 saw 75% GAAP gross margin and 86.4% subscription gross margin, with continued product adoption fueling growth. Management raised FY2027 guidance and targets a $6 billion revenue run rate by 2030, with Q2 revenue expected to exceed guidance. Valuation risk has moderated, with VEEV now trading at 44x trailing and 38x forward earnings as the company grows into its premium multiple. Read the full article on Seeking Alpha
User avatar
ナラティブ更新 • Aug 27

Veeva Just Had a Great Quarter. That's Exactly Why I'm Not Buying More.

Revenue beat. Earnings beat.
User avatar
ナラティブ更新 • Aug 20

VEEV: AI Demand And CRM Wins Will Support Balanced Future Returns

Veeva Systems' analyst-derived fair value estimate has moved from $245.48 to $251.43 as analysts factor in Street research pointing to steadier normalized billings growth, customer interest in AI and CRM offerings, and mixed but generally constructive views on long term demand. Analyst Commentary Recent Street views on Veeva Systems show a wide range of opinions on execution, growth durability, and how current pricing lines up with perceived fundamentals.
User avatar
ナラティブ更新 • Jul 13

VEEV: AI Disruption Fears Will Pressure Core CRM Durability

Veeva Systems' updated analyst price target has been reduced from about $232.80 to $165.00. Analysts cite slightly lower modeled revenue growth, a lower assumed future P/E multiple, and ongoing debates around AI disruption and competitive pressure in core CRM offerings, despite steady Q1 execution and continued AI product development.
User avatar
新しいナラティブ • Jul 03

AI-Powered Veeva Systems Poised for Solid Growth Amid Regulatory Stability

Investors often look for artificial intelligence winners in the obvious places: semiconductors, hyperscalers, and general-purpose software platforms. But some of the most durable AI opportunities may sit in far less glamorous places—inside the regulated workflows where a mistake is not merely inconvenient, but potentially delays a drug trial, a regulatory submission, or a therapy reaching patients.
User avatar
ナラティブ更新 • Jun 29

VEEV: AI Execution And CRM Wins Will Drive Future Upside

Veeva Systems’ analyst fair value estimate has been reset lower from about $380 to roughly $338, reflecting Street price target cuts as analysts weigh solid Q1 execution against AI disruption risk, competitive CRM questions, and a shift toward more measured profit margin and P/E assumptions. Analyst Commentary Street research on Veeva Systems presents a mixed but generally constructive picture, with many firms recalibrating price targets while still pointing to solid Q1 execution, ongoing demand in health technology, and emerging AI and CRM catalysts as key elements in their valuation work.
分析記事 • Jun 20

Veeva Systems (VEEV) Stock Could Be 38% Undervalued After Fed Driven Pullback

Veeva Systems (VEEV) shares fell after the Federal Reserve held its benchmark rate and signaled a more restrictive stance, as higher Treasury yields weighed on software sector valuations, including healthcare and life sciences platforms. See our latest analysis for Veeva Systems. At around US$153.30, Veeva Systems’ recent share price weakness has been broad based, with a 1 day share price return of 1% and a year to date share price return down 30.16%, while the 1 year total shareholder return...
User avatar
ナラティブ更新 • Jun 15

VEEV: AI Execution And CRM Wins Will Support Future Multiple Reacceleration

Narrative Update The analyst price target for Veeva Systems in this framework is updated from about $263 to about $245, as analysts balance solid Q1 execution and raised guidance with AI disruption risk, CRM competition from Salesforce, and questions around the quality and mix of recent upside, particularly in services. Analyst Commentary Recent research on Veeva Systems reflects a split view, with most analysts acknowledging solid Q1 execution and raised guidance, but debating how much weight to give AI disruption risk, CRM competition, and the quality of services driven upside when thinking about valuation, execution, and long term growth.
User avatar
ナラティブ更新 • Jun 01

VEEV: AI Moat And CRM Commitments Will Support Future Multiple Reacceleration

Narrative Update The analyst price target for Veeva Systems has been trimmed by about $2 to $262.68 as analysts factor in compressed software multiples, while largely maintaining their underlying growth, margin, and P/E assumptions. Analyst Commentary Recent research on Veeva Systems clusters around strong reported execution in Q4, tempered by valuation resets tied to compressed software multiples and longer term questions around AI and CRM competition.
User avatar
ナラティブ更新 • May 11

VEEV: AI Moat And CRM Commitments Will Support Premium Multiple

Veeva Systems' updated analyst price target edges lower to about $264 from roughly $265, as analysts keep their broadly positive take on the company's recent Q4 results but adjust valuation assumptions to reflect compressed software multiples and ongoing debates around AI, R&D growth, and CRM stability. Analyst Commentary Recent research on Veeva reflects a mix of optimism about execution in Q4 and caution around valuation and longer term growth drivers.
User avatar
ナラティブ更新 • Apr 25

VEEV: AI Moat And Subscription Resilience Will Support Premium Multiple

Analysts have trimmed the Veeva Systems price target slightly, with the model fair value moving from about $270.93 to $264.46, as modestly lower assumed future P/E multiples more than offset largely unchanged growth and margin expectations. Analyst Commentary Recent Street research around Veeva Systems shows a split view, with many firms trimming price targets while still pointing to solid execution and specific areas of uncertainty that could influence the valuation over time.
User avatar
ナラティブ更新 • Apr 08

VEEV: AI And Subscription Resilience Will Support Premium Software Multiple

Analysts trimmed the blended Veeva Systems price target by aligning with sector wide software multiple compression, even as they point to strong Q4 execution, resilient subscription growth, and an emerging AI and product pipeline as key longer term supports. Analyst Commentary Recent Street research around Veeva Systems reflects a mix of optimism on execution and growth, alongside more cautious views on competitive risk, AI impact, and valuation.
User avatar
ナラティブ更新 • Mar 25

VEEV: AI Adoption In R&D Workflows Will Support Durable Premium Outlook

Analysts have adjusted their price targets on Veeva Systems into a roughly $190 to $317 range, generally trimming prior targets by tens of dollars as software valuation multiples compress, even after what they describe as solid Q4 results and broadly constructive longer term fundamentals. Analyst Commentary Recent research paints a mixed but generally constructive picture for Veeva Systems, with most firms trimming price targets while still pointing to solid execution and durable fundamentals.
User avatar
ナラティブ更新 • Mar 11

VEEV: AI Adoption And CRM Commitments Will Support Durable Premium Outlook

We are trimming our Veeva Systems fair value estimate to $270.93 from $302.60, as analysts broadly reset price targets in response to sector wide software multiple compression and slightly more measured assumptions for revenue growth, margins, and future P/E multiples, despite generally solid Q4 results and guidance. Analyst Commentary Street research on Veeva Systems has become more mixed, with many firms cutting price targets while still acknowledging solid Q4 execution and robust profitability.
User avatar
ナラティブ更新 • Feb 25

VEEV: AI Execution And CRM Stability Will Support Durable Premium Outlook

Our fair value estimate for Veeva Systems has edged down from $308.63 to $302.60. This reflects a series of reduced Street price targets as analysts weigh maturing products, competitive pressures, software sentiment, and the balance of growth opportunities against current valuation.
User avatar
ナラティブ更新 • Feb 10

VEEV: Roche Commitment And CRM Retention Will Support Durable Premium Outlook

Our analyst fair value estimate for Veeva Systems has been trimmed slightly to $308.63. This reflects a modest reset in Street price targets as analysts balance concerns about slower growth in maturing products and competitive pressure with ongoing strengths in areas like Crossix, AI adoption, and large CRM wins such as Roche.
User avatar
新しいナラティブ • Jan 28

Rising Life Sciences Cloud Standardization And AI Adoption Will Support Strong Long Term Upside

Catalysts About Veeva Systems Veeva Systems provides cloud based software, data and consulting services to life sciences companies across commercial, R&D and manufacturing functions. What are the underlying business or industry changes driving this perspective?
User avatar
ナラティブ更新 • Jan 27

VEEV: Roche Rollout And CRM Retention Will Support Durable Premium Outlook

The analyst price target embedded in our Veeva Systems model edges slightly lower to about US$310 from roughly US$311. This reflects a blend of more cautious views on growth and competitive pressure, along with offsetting positive views on durable margins, CRM customer retention, and newer areas such as Crossix and early AI traction.
User avatar
ナラティブ更新 • Jan 12

VEEV: Roche Expansion And CRM Migrations Will Support Durable Premium Outlook

Analysts have trimmed their fair value estimate for Veeva Systems by about US$1 to US$310.98, reflecting modest adjustments to discount rate and growth assumptions while still pointing to what they see as durable growth drivers such as pharma CRM migrations, broader Vault adoption and newer areas like Crossix and AI. Analyst Commentary Recent Street research on Veeva Systems reflects a mix of optimism and caution, with differing views clustering around the durability of growth in CRM and Vault, the timing of pharma migrations, and how current valuation stacks up against execution and contract wins.
User avatar
ナラティブ更新 • Dec 19

VEEV: Roche Commitment And CRM Migrations Will Likely Sustain Premium Outlook

Analysts have modestly trimmed their blended price target for Veeva Systems to about $312 from roughly $321, reflecting a slightly higher discount rate and lower implied future multiple, even as they highlight accelerating CRM migrations, including Roche's global Vault CRM rollout, and improving long term growth and margin expectations. Analyst Commentary Street research remains broadly constructive on Veeva Systems, with recent target changes reflecting a recalibration of software multiples rather than a material shift in company specific fundamentals.
分析記事 • Dec 03

Veeva Systems' (NYSE:VEEV) Performance Is Even Better Than Its Earnings Suggest

Investors were underwhelmed by the solid earnings posted by Veeva Systems Inc. ( NYSE:VEEV ) recently. We have done...
User avatar
ナラティブ更新 • Nov 11

VEEV: Continued Momentum And New Commitments Will Likely Sustain Premium Outlook

Analysts have significantly raised their price targets on Veeva Systems, with recent updates moving targets as high as $380. They cite the company's strong sales growth prospects and solid momentum, driven by accelerating CRM customer commitments and new partnerships.
User avatar
ナラティブ更新 • Oct 27

Pharma Wins And New Partnerships Will Drive Cloud Momentum In Coming Quarters

Veeva Systems' analyst price target saw a significant increase, rising by more than $80 to reflect higher expectations for sales growth and ongoing customer commitments. Analysts cited the company’s strengthening position in CRM and positive momentum across key pharma relationships.
User avatar
ナラティブ更新 • Oct 13

IQVIA Resolution And Embedded AI Will Expand Digital Healthcare Cloud

Narrative Update on Veeva Systems: Analyst Price Target Revision Analysts have raised their fair value estimate for Veeva Systems to approximately $321 per share, up by nearly $4. They cited stronger than expected sales momentum, driven by new major customer commitments and continued growth in key business segments.
User avatar
ナラティブ更新 • Aug 29

Data Cloud Expansion And AI Efficiencies Will Drive Future Success

Analysts have raised their price target for Veeva Systems to $314.71, citing strong Q2 “beat and raise” results, momentum in both Commercial and R&D segments, successful Vault CRM rollouts with major pharma clients, and ongoing market share gains in life sciences CRM. Analyst Commentary Bullish analysts highlighted Veeva's strong “beat and raise” Q2 results, with both subscription and services revenues growing solidly year-over-year, driven by performance in both Commercial and R&D technology segments.
Seeking Alpha • Apr 17

Veeva Systems: Substantially Overvalued As Growth Slows

Summary Veeva Systems is overvalued, trading at frothy levels despite only ~10% growth, and facing a potential slowdown in 2025; I recommend a sell rating. The company excels in the life sciences vertical with unique solutions but its ambitious revenue targets (doubling revenue by 2030) may be tough to achieve organically. Valuation multiples are high at ~10 EV/FY26 revenue and ~30x FY26 P/E, well above a number of peers - some of which are growing even faster than Veeva. Read the full article on Seeking Alpha
Seeking Alpha • Mar 19

Veeva Systems: Staying Buy Rated As VEEV Is Executing Well

Summary I reaffirm my buy rating on Veeva Systems due to strong 4Q25 results, driven by R&D growth and positive Vault CRM adoption traction. VEEV's revenue grew 14% y/y to $721 million, beating expectations, with significant margin improvements and a strong balance sheet. Vault CRM added 20 new customers, with multiple top 20 pharma commitments expected in 2025, signaling positive transition progress. Data Cloud segment shows strong momentum, with new initiatives like Pulse expected to drive further CRM adoption and growth. Read the full article on Seeking Alpha
Seeking Alpha • Mar 07

Veeva Systems: Solid Q4 With Margin Expansion

Summary I reiterate my “Strong Buy” rating on Veeva Systems Inc. with a one-year target price of $275 per share due to strong CRM migration and margin improvement. Veeva reported 14.3% revenue growth and 28.7% adjusted operating profit growth, driven by robust CRM adoption and billing growth. Management's guidance for FY26 includes $3.04-$3.055 billion in revenue, with anticipated 12% revenue growth despite high-interest rate challenges. I foresee continued margin expansion and revenue growth recovery to 16% by FY27 for VEEV, supported by CRM migration and easing capital funding challenges. Read the full article on Seeking Alpha

株主還元

VEEVUS Healthcare ServicesUS 市場
7D1.1%4.1%0.5%
1Y-5.5%-17.5%12.0%

業界別リターン: VEEV過去 1 年間で-17.5 % の収益を上げたUS Healthcare Services業界を上回りました。

リターン対市場: VEEVは、過去 1 年間で12 % のリターンを上げたUS市場を下回りました。

価格変動

Is VEEV's price volatile compared to industry and market?
VEEV volatility
VEEV Average Weekly Movement7.0%
Healthcare Services Industry Average Movement10.4%
Market Average Movement6.8%
10% most volatile stocks in US Market15.2%
10% least volatile stocks in US Market2.9%

安定した株価: VEEV 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。

時間の経過による変動: VEEVの 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。

会社概要

設立従業員CEO(最高経営責任者ウェブサイト
20077,928Peter Gassnerwww.veeva.com

Veeva Systems Inc.は、北米、欧州、アジア太平洋地域、中東、アフリカ、中南米のライフサイエンス業界向けにクラウドベースのソフトウェアを提供している。製薬・バイオ企業向けのVeeva Vault CRM SuiteからなるVeeva Commercial Cloud、複数のチャネルや地域にまたがる医療コンテンツのソースを提供するVeeva Medical、エンドツーエンドのコンテンツおよびデジタル資産管理ソリューションであるVeeva PromoMats、製薬ブランド向けの分析プラットフォームであるVeeva Crossixを提供している。また、Veeva Data Cloudとして、顧客参照データソリューションのVeeva OpenData、ディープデータを提供するVeeva Link、非識別化・縦断的な患者データを含むVeeva Compass、アクセスとマルチチャネルのエンゲージメントメトリクスを提供するVeeva CRM Pulseなどを提供している。さらに、臨床試験の実施を促進するVeeva Clinical Platform、スポンサーやCROが臨床試験を設計・実施するのを支援するVeeva Clinical Data Management、システムやプロセスを統合するVeeva Safety、規制情報管理機能を提供するVeeva RIM、ライフサイエンスや消費者製品業界で使用されるVeeva Quality Cloud、Veeva Business Consultingサービスで構成されるVeeva Development Cloudを提供している。さらに、導入・展開計画、プロジェクト管理、要件分析、ソリューション設計、構成、システム環境管理、展開、ビジネスや業務プロセスの改善・変革に焦点を当てたサービス、データ移行やシステム統合に関する技術コンサルティングサービス、トレーニング、システム管理のアウトソーシングなど継続的なマネージドサービスなど、専門的なサポートサービスも提供している。2009年4月に社名をVeeva Systems Inc.に変更。2007年に法人化され、カリフォルニア州プレザントンに本社を置いている。

Veeva Systems Inc. 基礎のまとめ

Veeva Systems の収益と売上を時価総額と比較するとどうか。
VEEV 基礎統計学
時価総額US$42.89b
収益(TTM)US$1.01b
売上高(TTM)US$3.46b
42.1x
PER(株価収益率
12.3x
P/Sレシオ

VEEV は割高か?

公正価値と評価分析を参照

収益と収入

最新の決算報告書(TTM)に基づく主な収益性統計
VEEV 損益計算書(TTM)
収益US$3.46b
売上原価US$865.88m
売上総利益US$2.59b
その他の費用US$1.58b
収益US$1.01b

直近の収益報告

Jul 31, 2026

次回決算日

該当なし

一株当たり利益(EPS)6.27
グロス・マージン74.96%
純利益率29.34%
有利子負債/自己資本比率0%

VEEV の長期的なパフォーマンスは?

過去の実績と比較を見る

企業分析と財務データの現状

データ最終更新日(UTC時間)
企業分析2026/09/17 22:07
終値2026/09/17 00:00
収益2026/07/31
年間収益2026/01/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
  • SECフォーム10-K
  • SECフォーム10-Q
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
  • アナリストリサーチレポート
  • Blue Matrix
市場価格30年
  • 株価
  • 配当、分割、措置
  • ICEマーケットデータ
  • SECフォームS-1
所有権10年
  • トップ株主
  • インサイダー取引
  • SECフォーム4
  • SECフォーム13D
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
  • SECフォーム10-K
  • SECフォームDEF 14A
主な進展10年
  • 会社からのお知らせ
  • SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Veeva Systems Inc. 27 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。47

アナリスト機関
Joseph VruwinkBaird
Saket KaliaBarclays
"Saket KaliaBarclays

どこでもより良い投資判断を

スキャンしてダウンロード
App Store を開くGoogle Play を開く
Chrome ウェブストア
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
データソースを見る
市場
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
投資のアイデア
  • 割安企業
  • 配当優良企業
  • インサイダー買い
  • 原子力
  • 自律走行車
  • 人工知能
  • 暗号資産とブロックチェーン
  • サイバーセキュリティ
  • さらにアイデア
株価コミュニティ
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
機能とツール
  • ポートフォリオ・トラッカー
  • ストックスクリーナー&アラート
  • 語りと公正な値
  • 配当金計算機
ニュース & 発見
  • 最新の在庫ニュース
  • グローバルマーケットインサイト
  • The Foxhole ブログ
  • 投資のアイデア
  • コミュニティの物語
  • 新着情報
Simply Wall St
  • プランと料金
  • 広告
  • 会社概要
  • お問い合わせ
  • 採用情報
  • ヘルプセンター
  • 株式投資を学ぶ
  • アフィリエイト・プログラム
  • ビジネス
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • ご利用条件
  • プライバシーポリシー
  • AI利用規約
  • 金融サービスガイド